RASGEF1B

Across TCGA pan-cancer cohorts, RASGEF1B RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of RASGEF1B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney chromophobe (KICH), where RASGEF1B RNA is repressed in tumor relative to normal tissue. In most cancer types RASGEF1B is over-expressed in tumor, although a few such as KICH and LUAD show the opposite, repressed pattern.

KICH, LUAD, and LUSC are the cancer types where RASGEF1B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RASGEF1B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KICH	Female	II,III,IV	−1.751	<.001	9	view →
LUAD	Female	III,IV	−1.421	<.001	9	view →
LUSC	Male	II,III,IV	−1.802	<.001	8	view →
THCA	Male	III,IV	+1.708	<.001	6	view →
BRCA	All	III,IV	−0.805	<.001	6	view →
BLCA	All	All	−0.523	.006	6	view →
LIHC	Female	All	−1.156	<.001	5	view →
READ	All	All	−0.430	.010	4	view →
CHOL	All	All	−1.137	<.001	3	view →
KIRP	All	All	+0.576	.007	2	view →
HNSC	All	II,III,IV	−0.341	.022	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

RASGEF1B–KICH

Open the KICH breakdown →